Bisphosphonate treatment in children with acute lymphoblastic leukemia and osteonecrosis – radiological and clinical findings in a national cohort
- 26 July 2021
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 60 (9) , 1140-1145
Abstract
Background: Osteonecrosis (ON) is a recognized complication of childhood ALL, but its optimal management remains unestablished. This study evaluated the effect of bisphosphonate (BP) treatment on the evolution of ON lesions in childhood ALL. Material and Methods: We included a national cohort of ALL patients diagnosed with symptomatic ON before 18 years of age and treated with BPs (N = 10; five males). Patients were followed both clinically and with serial MRIs. ON lesions were graded according to the Niinimäki classification. Results: The 10 patients had a total of 55 ON lesions. The median age was 13.3 years at ALL diagnosis and 14.8 years at ON diagnosis. Four patients had received HSCT before the ON diagnosis. BPs used were pamidronate (N = 7), alendronate (N = 2) and ibandronate (N = 1). The duration of BP treatment varied between 4 months and 4 years. In 4/10 patients, BP treatment was given during the chemotherapy. BPs were well-tolerated, with no severe complications or changes in kidney function. At the end of follow up 13/55 (24%) ON lesions were completely healed both clinically and radiographically; all these lesions were originally graded 3 or less. In contrast, ON lesions originally classified as grade 5 (joint destruction; N = 4) remained at grade 5. All grade 5 hip joint lesions needed surgical treatment. During BP treatment, the pain was relieved in 7/10 patients. At the end of follow-up, none of the patients reported severe or frequent pain. Conclusion: BP treatment was safe and seemed effective in relieving ON-induced pain in childhood ALL. After articular collapse (grade 5) lesions did not improve with BP treatment. Randomized controlled studies are needed to further elucidate the role of BPs in childhood ALL-associated ON.Keywords
Funding Information
- Research Council of Finland
- Väre Foundation for Childhood Cancer Research
- Finnish Pediatric Research Foundation
- Swedish Childhood Cancer Foundation
- University of Helsinki Fund
This publication has 21 references indexed in Scilit:
- Skeletal Morbidity in Children and Adolescents during and following Cancer TherapyHormone Research in Paediatrics, 2018
- Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemiaPediatric Blood & Cancer, 2018
- Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemiaLeukemia, 2017
- Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challengeBlood Advances, 2017
- Osteonecrosis in children with acute lymphoblastic leukemiaHaematologica, 2016
- Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemiaHaematologica, 2014
- Incidence of Severe Osteonecrosis Requiring Total Joint Arthroplasty in Children and Young Adults Treated for Leukemia or Lymphoma: A Nationwide, Register-Based Study in Finland and DenmarkJournal of Adolescent and Young Adult Oncology, 2013
- Causes, mechanisms and management of paediatric osteoporosisNature Reviews Rheumatology, 2013
- Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trialThe Lancet Oncology, 2012
- High Body Mass Index Increases the Risk for Osteonecrosis in Children With Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2007